echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Forecast of development trends in the field of biomedicine in 2020

    Forecast of development trends in the field of biomedicine in 2020

    • Last Update: 2020-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Knowledge and Practice In 2019, FDA approved a total of 48 innovative drugs, many first in class therapies were approved, and biological similar drugs developed rapidly In 2019, the investment heat of the pharmaceutical industry continued Two large-scale pharmaceutical M & A accounted for 2 / 3 of the total amount of M & A in the whole year Various technologies have become mature one after another, and the clinical trials of small pharmaceutical enterprises have shown positive results In 2020, how will the biomedical industry develop? The following five points deserve attention On November 20, 2019, Bristol Myers Squibb completed the acquisition of celgene, and the old pharmaceutical company celgene, which has been operating for 34 years, ended On June 25, 2019, abbvie announced the acquisition of Allergan, which will become the fourth largest pharmaceutical company in the world Allergan will increasingly talk about people's vision Although Amgen, Biogen, Gilead, regeneron and vertex are currently independent, they are not allowed to merge in the future in the face of the increasingly severe biomedical industry The pattern of biomedical enterprises is quietly changing Other large and medium-sized pharmaceutical enterprises with a value of 10-20 billion US dollars, such as alexion, biomarin, Seattle genetics, Alnylam and Sarepta, are becoming new wind vane for pharmaceutical enterprises Take alexion and biomarin for example Alexion has a number of products on the R & D pipeline In the second half of 2018, FDA approved its ultomiris launch, which is the follow-up product of soliris on alexion's sales list In October 2019, alexion announced to purchase Achillion for $930 million in cash to strengthen its R & D pipeline Biomarin focuses on the development of innovative therapies for severe and life-threatening rare and ultra rare genetic diseases, and has made milestone progress It has submitted the world's first gene therapy valrox for hemophilia A to EMA and FDA If valrox is approved for marketing in 2020, it will consolidate biomarin's position as a leader in gene therapy In the past, biopharmaceutical technology mainly refers to macromolecular therapy produced by living cells After more than 40 years of development, biopharmaceutical technology has become increasingly diversified, and a more complex new drug research and development platform has been formed, ranging from new applications based on monoclonal antibodies, to nucleic acid (RNA) therapy, to gene therapy In 2019, important progress has been made in RNAi therapy and gene therapy, confirming the feasibility of new technology and its potential in the field of new drug development After the world's first RNAi therapy, onpattro, was approved for marketing in 2018, in November 2019, FDA again approved Alnylam's second RNAi therapy, givlaari, for the treatment of adult patients with acute porphyria (AHP) The success of onpattro and Alnylam stimulated large pharmaceutical companies to start cooperation with dicerna and arrowhead, companies focusing on RNAi therapy Novartis also acquired medicines in November 2019 in order to enter the RNAi field Gene therapy has also become the target of drug companies, spark, nightstar and audentes have gradually become popular drug companies In 2019, zolgensma was listed at a high price of US $2.1 million, and achieved the expected sales volume The expensive gene therapy will also have a market In addition, car-t therapy and double antibody products are frequently reported, and diversified and mature biotechnology platforms will bring more choices for patients In 2019, the amount of M & A among biopharmaceutical enterprises reached a record high Among the three largest M & A cases, Bristol Myers Squibb acquired celgene, abbvie acquired Allergan and Amgen acquired celgene product otezla, contributing a total of US $150 billion, among which Bristol Myers Squibb acquired celgene with us $74 billion, ranking the highest in history Top 10 acquisition of biomedical enterprises in 2019 Large pharmaceutical enterprises can quickly obtain the candidate products of other pharmaceutical enterprises in the middle and late stage of R & D through M & A, concentrate resources to 3-4 major disease areas, and obtain competitiveness in the main direction to ensure long-term and healthy development Excellent clinical data also urges pharmaceutical enterprises to eliminate competition and supplement themselves through M & A Premium acquisition is a common way in M & A, while in synthorx, arqule, audentes and RA pharmaceuticals, the premium is close to or more than 100%, which shows its attraction In addition, Novartis's acquisition of medicines Co in turn promoted the development of RNAi therapy On January 6, 2020, Eli Lilly announced the acquisition of dermira for us $1.1 billion Before J.P Morgan conference, Eli Lilly launched the first acquisition of pharmaceutical companies in 2020 The recent J.P Morgan conference will open the curtain of M & A of pharmaceutical enterprises in 2020, and will also affect the development direction of Biopharmaceutics in 2020 It remains to be seen New drug research and development needs a lot of capital investment With more and more biomedical enterprises springing up, it needs a lot of stable capital to maintain the operation of their laboratories According to RBC statistics, in 2019, biopharmaceutical enterprises received a total of US $33 billion in capital investment, which is not as high as that in 2018, but also higher than that in 2016 and 2017, among which the issuance of secondary shares is the main form for pharmaceutical enterprises to obtain funds The question now is, will there be so much capital inflow in 2020? There are more and more pharmaceutical companies and investors are more and more picky RBC estimates that more than 200 pharmaceutical companies will need to raise funds in 2020 If there is no external capital inflow, half of them will not survive 2020 10 years + 1 billion US dollars is the total investment of a new drug successfully launched In the past, investors believed that small pharmaceutical companies would invest too much time and resources in R & D stage, and doubted the production problems of new drugs after they went on the market But now the situation has changed, and the small pharmaceutical enterprises created in succession have promoted more supporting enterprises such as R & D and production Many small pharmaceutical companies, such as GW pharmaceuticals, karyopharm and Acadia, have products on the market, while neurocrine is more competitive with Teva In November 2019, oxbryta, an innovative therapy of global blood therapeutics, was approved for marketing, providing a new choice for patients with sickle cell anemia In December 2019, vascepa, amarin's fish oil product, was expanded to be the first drug to assist statins in reducing cardiovascular risk in high-risk patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.